Oncoimmunostics Limited

Oncoimmunostics Limited is a start-up biotech company spun off from University of Hong Kong in 2022. The company is established by Chair Professor Nancy Kwan Man, a professional of transplant oncology and immunology in the world. Oncoimmunostics focuses on precise cancer diagnostics and therapeutics. To tackle the problem of high recurrence rate and low drug response rate in liver cancer, we apply 3D bioprinting technology to invent the biomimetic liver cancer microenvironment "liver-in-cube" which can be used for personalized drug screening for choosing the best treatment. The product can also be used for new drugs development and safety assessment in the pharmaceutical industry, and can be widely applied in basic research for tumor microenvironment. This product has a short manufacturing time, high biomimicry, and is superior to current 3D culture and organoid models, replacing the use of animal models. The company has a strong clinical, basic and translational research team, owns world-leading research outputs in the field of tumor immune microenvironment, possesses a comprehensive tissue bank and patients database. Future directions include developing multiple cancer models to promote early diagnosis, treatment, and precise treatment of cancer.